MEFENAMIC ACID

Search structure


Trade Names:	MEFENAMIC ACID PONSTEL
Synonyms:	CI-473 CN-35355 Contraflam Dysman-250 Dysman-500 Gardan INF-3355 J2.344B M01AG01 Mefenamic acid Mefenaminic acid Meflam 250 Meflam 500 Mendys Mephenamic acid Mephenaminic acid NSC-94437 Opustan 250 Opustan 500 Ponstan Ponstan fte Ponstel
Status:	Approved (1967)
Entry Type:	Small molecule
Molecule Category:	Parent
ATC:	M01AG01
UNII:	367589PJ2C

Structure


InChI Key	HYYBABOKPJLUIN-UHFFFAOYSA-N
Smile	Cc1cccc(Nc2ccccc2C(=O)O)c1C
InChI	InChI=1S/C15H15NO2/c1-10-6-5-9-13(11(10)2)16-14-8-4-3-7-12(14)15(17)18/h3-9,16H,1-2H3,(H,17,18)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C15H15NO2
Molecular Weight	241.29
AlogP	3.75
Hydrogen Bond Acceptor	2.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	3.0
Polar Surface Area	49.33
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	18.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Cyclooxygenase inhibitor	PubMed PubMed

	Primary Target
COX-1
COX-2

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Hydrolase	-	6120	-	-	-
Enzyme Oxidoreductase	-	980-2210	-	220	-
Enzyme Phosphodiesterase Phosphodiesterase 4 Phosphodiesterase 4B	-	-	-	-	39
Enzyme Phosphodiesterase Phosphodiesterase 4 Phosphodiesterase 4D	-	-	-	-	36
Enzyme Protease Serine protease Serine protease PA clan Serine protease S1A subfamily	-	-	-	-	41
Enzyme	-	980-2210	-	220	36
Ion channel Voltage-gated ion channel Transient receptor potential channel	16000-61000	-	-	-	-
Secreted protein	-	-	-	-	93
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	63
Transporter Primary active transporter ATP-binding cassette ABCB subfamily	-	57000	-	-	-
Unclassified protein	-	25000	-	-	-

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
Hemorrhage	3	D006470	ClinicalTrials
Pain	2	D010146	ClinicalTrials
Diabetes Mellitus	1	D003920	ClinicalTrials

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
Gastrointestinal disorders	17.82
Injury, poisoning and procedural complications	14.85
Nervous system disorders	11.88
General disorders and administration site conditions	10.89
Immune system disorders	7.92
Skin and subcutaneous tissue disorders	7.92
Psychiatric disorders	6.93
Vascular disorders	4.95
Reproductive system and breast disorders	3.96
Cardiac disorders	2.97
Infections and infestations	2.97
Renal and urinary disorders	2.97

Cross References

Resources	Reference
CAS NUMBER	61-68-7
ChEBI	6717
ChEMBL	CHEMBL686
DrugBank	DB00784
DrugCentral	1663
EPA CompTox	DTXSID5023243
FDA SRS	367589PJ2C
Human Metabolome Database	HMDB0014922
Guide to Pharmacology	2593
KEGG	C02168
PDB	ID8
PharmGKB	PA450347
PubChem	4044
SureChEMBL	SCHEMBL3544
ZINC	ZINC000000020241

CONTENTS